CHMP forlangte derfor, at indehaveren af markedsføringstilladelsen tager passende skridt til at sikre, at Protopic ikke anvendes i denne aldersgruppe.
Therefore the CHMP requested that the MAH should take the appropriate measures in order to ensure that Protopic is not used in this age group.